What if the next major advance in AML trials wasn’t a new molecule but a better endpoint??
At ASH25, Christian Recher (CHU de Toulouse / ALFA Groupes Coopérateurs en Oncologie) presented a strong proposal:
Salvage-free, transplantation-free survival (STFS) as a novel endpoint to better capture the true impact of frontline AML therapies.
As intensive chemotherapy is increasingly combined with targeted agents, traditional endpoints (OS, EFS, RFS) are often confounded by subsequent treatments such as allo-HSCT or salvage therapy.
? STFS refocuses the question on what really matters:
curing more patients after first-line treatment, without transplantation or additional salvage.
Based on nearly 2,000 patients from the DATAML registry, this work highlights both the unmet need across AML subgroups and the value of STFS as a clearer, more actionable endpoint for future trials. ??
ALFA - Acute Leukemia French Association with Institut Carnot OPALE is ready to integrate STFS into its studies and to work with partners willing to rethink how efficacy is measured in AML.
? ASH Abstract #450